Karyopharm Therapeutics Inc
$ 8.16
12.55%
09 Apr - close price
- Market Cap 183,953,000 USD
- Current Price $ 8.16
- High / Low $ 8.25 / 7.19
- Stock P/E N/A
- Book Value -16.00
- EPS -20.13
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.42 %
- ROE -8.91 %
- 52 Week High 10.99
- 52 Week Low 3.65
About
Karyopharm Therapeutics Inc., a pharmaceutical company, is dedicated to the discovery, development and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts.
Analyst Target Price
$11.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-12 | 2025-11-05 | 2025-08-11 | 2025-05-12 | 2025-02-19 | 2024-11-05 | 2024-08-06 | 2024-05-08 | 2024-02-29 | 2023-11-02 | 2023-08-02 | 2023-05-04 |
| Reported EPS | -5.69 | -3.82 | -4.07 | -2.77 | -3.6 | -3.9 | 0.15 | -0.32 | -0.36 | -0.3 | -0.29 | -0.3 |
| Estimated EPS | -0.2125 | -2.21 | -3.91 | -3.09 | -4.03 | -3.92 | -0.3 | -0.33 | -0.31 | -0.28 | -0.34 | -0.37 |
| Surprise | -5.4775 | -1.61 | -0.16 | 0.32 | 0.43 | 0.02 | 0.45 | 0.01 | -0.05 | -0.02 | 0.05 | 0.07 |
| Surprise Percentage | -2577.6471% | -72.8507% | -4.0921% | 10.356% | 10.67% | 0.5102% | 150% | 3.0303% | -16.129% | -7.1429% | 14.7059% | 18.9189% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.45 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KPTI
2026-04-10 05:40:28
The article reports that the price target for Karyopharm Therapeutics (KPTI) has been decreased by 22.08%, bringing it down to $12.24. This change indicates a significant adjustment in the expected valuation of the company's stock by analysts.
2026-04-07 17:43:21
RBC Capital has adjusted its price target for Karyopharm Therapeutics (KPTI) to $16, down from the previous target of $23. Despite this reduction, the firm has maintained an Outperform rating on the company's stock. This change reflects RBC Capital's updated outlook for Karyopharm Therapeutics.
2026-04-07 12:39:06
RBC Capital has adjusted its price target for Karyopharm Therapeutics (KPTI) to $16 from $23, while maintaining an Outperform rating. This change comes shortly after news of Karyopharm Therapeutics Inc. expecting to receive $29.999661 million in funding from RA Capital Management, L.P. The company also recently reported positive topline results from its Phase 3 SENTRY trial in Myelofibrosis.
2026-04-03 08:40:54
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received a consensus "Moderate Buy" rating from eight brokerages, with an average 12-month price target of $14.29. While several analysts recently lowered their price targets, Rodman & Renshaw upgraded the stock to a "strong-buy." The company, which sells the approved drug selinexor (XPOVIO) and has other pipeline programs, faces a market capitalization of $108 million and is currently loss-making.
2026-04-02 21:09:06
RA Capital Management and affiliated reporting persons have disclosed a 9.99% beneficial ownership stake in Karyopharm Therapeutics Inc. (NASDAQ: KPTI), totaling 2,078,913 shares. This stake includes direct holdings, pre-funded warrants, and common warrants, all of which are subject to "Beneficial Ownership Blockers" to prevent ownership exceeding 9.99%. The filing clarifies the delegation of voting and disposition powers to RA Capital, disclaims "group" status under SEC rules, and provides key figures regarding the reported ownership.
2026-04-02 20:09:06
Commodore Capital and related entities have disclosed a 9.9% beneficial ownership stake in Karyopharm Therapeutics Inc. (KPTI), amounting to 1,950,000 shares. This disclosure, made via a Schedule 13G filing, indicates a passive investment based on 19,618,032 shares outstanding as of March 23, 2026. The filers include Commodore Capital LP, Commodore Capital Master LP, and managing partners Michael Kramarz and Robert Egen Atkinson.
